Considering that MDS is a hematological malignancy that presents clonal hematopoiesis, it is important to establish the VAF of certain genes, and Jiang et al. recommended a routine investigation of the mutational VAF of certain genes (TET2, TP53, ZRSR2, RUNX1, and DNMT3A) for the outcome prediction and leukemic transformation [54]. The gene discussed is DNMT3A; the disease is myelodysplastic syndrome.